Samsung Biologics has signed a large-scale contract manufacturing agreement for pharmaceuticals with a European pharmaceutical company.

Panoramic view of Samsung Biologics Plant 4 in Songdo, Incheon. Samsung Biologics

Panoramic view of Samsung Biologics Plant 4 in Songdo, Incheon. Samsung Biologics

View original image

On March 13, Samsung Biologics announced through a public disclosure that it had signed a contract manufacturing agreement for pharmaceuticals worth 279.6 billion won with a European pharmaceutical company. This amount is equivalent to 6.15% of its consolidated revenue of 4.5473 trillion won in 2024.


The contract period began on July 31, 2025, and is scheduled to end on March 13, 2032. However, the termination date may be subject to change based on mutual agreement between the two parties.



The specific name of the European pharmaceutical company, which is the counterparty to the contract, was not disclosed due to business confidentiality reasons.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing